Showing results (281-290 of 383) with videos related to
Sort By:
Pageof 39
American Heart Journal|February 1, 1989
Prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126 increase in proportion to right ventricular pacing rateL Ngo, R P Wyeth, J K Bissett, et al.The Journal of Foot Surgery|July 1, 1985
Management of puncture wounds in the footR P Reinherz, D T Hong, L M Tisa, et al.Biorxiv : the Preprint Server for Biology|March 30, 2023
Universal open MHC-I molecules for rapid peptide loading and enhanced complex stability across HLA allotypesYi Sun, Michael C Young, Claire H Woodward, et al.Australian Dental Journal|June 20, 2022
Dental procedures in children with or without intellectual disability and autism spectrum disorder in a hospital settingS Azimi, K Wong, Yyl Lai, et al.Thrombosis and Haemostasis|October 9, 2008
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery diseaseOscar O Braun, Matilda Johnell, Christoph Varenhorst, et al.Platelets|June 24, 2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjectsChristopher D Payne, Ying G Li, John T Brandt, et al.Thrombosis and Haemostasis|February 19, 2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationJoseph A Jakubowski, Christopher D Payne, Ying G Li, et al.Journal of Neurosurgery|February 13, 2002
Titanium miniplates or stainless steel wire for cranial fixation: a prospective randomized comparisonWilliam C Broaddus, Kathryn L Holloway, Charles J Winters, et al.American Heart Journal|March 3, 2009
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirinChristoph Varenhorst, Stefan James, David Erlinge, et al.Journal of Clinical Pharmacology|February 28, 2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrelDavid S Small, Nagy A Farid, Christopher D Payne, et al.Pageof 39